首页> 外文学位 >Medication Adherence Outcomes in Elderly Patients with Hypertension and Chronic Kidney Disease: a Geographical Approach
【24h】

Medication Adherence Outcomes in Elderly Patients with Hypertension and Chronic Kidney Disease: a Geographical Approach

机译:老年高血压和慢性肾脏病患者的药物依从性结果:地理方法

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: Chronic kidney disease (CKD) patients with uncontrolled blood pressure are at high risk of cardiovascular events, hospitalization, and mortality. There is limited research evaluating utilization patterns of anti-hypertensives in hypertensive CKD patients. This study aims to assess anti-hypertensives use, particularly, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) in the United States, and explore contextual and individual risk factors of treatment compliance.;METHODS: Hypertensive CKD patients were selected using Medicare 5% sample claims data from the United States Renal Data System (USRDS) databases (2006-2013). We included patients who diagnosed with hypertension and CKD, and followed them from Jan 1, 2008 to Dec 31, 2013. We first investigated medication treatment patterns among incident CKD patients. We then performed time-dependent survival analyses to evaluate long-term benefits of being adherence to ACEIs/ARBs. Medication adherence in this study was measured by proportion days covered (PDC). Lastly, we used geographically weighted regression model (GWR) to explore risk factors of medication adherence.;RESULTS: Approximately 50% of incident hypertensive CKD patients received guideline-recommended ACEIs/ARBs after their first diagnosis of CKD. Anti-hypertensive regimens including ACEIs/ARBs and statins yielded better CKD outcomes than regimens without these drugs. Additionally, continuously being adherent to ACEIs and ARBs was associated a significant decline in risk of end-stage renal disease (ESRD) and mortality in long run. However, only 61% of hypertensive CKD who used ACEIs/ARBs had good medication compliance (PDC ≥80%). Patients residing in the Northeast region and the Midwest region demonstrated better adherence than those residing in the Southern United States. Availability of primary resources, neighborhood deprivation status, and coverage of Part D Low-income Subsidy (LIS) were factors related with medication adherence. Geographically varied association between contextual characteristics and adherence were displayed by maps.;CONCLUSIONS: Utilization of guideline-recommended ACEIs/ARBs is suboptimal in elderly patients with hypertension and CKD in the United States, although they had significant long-term benefits on CKD outcomes. Adherence to ACEIs/ARBs is geographically differentiated across the United States. Contextual and individuals risk factors identified in this study are helpful to design population-based strategies in a local area to promote medication compliance, from a population perspective.
机译:目的:血压不受控制的慢性肾脏病(CKD)患者发生心血管事件,住院和死亡的风险很高。评估高血压CKD患者抗高血压药利用模式的研究有限。这项研究旨在评估抗高血压药的使用,尤其是在美国使用血管紧张素转换酶抑制剂(ACEIs)和血管紧张素受体阻滞剂(ARBs)的情况,并探讨治疗依从性的背景和个体风险因素。;方法:高血压CKD患者使用美国肾脏数据系统(USRDS)数据库(2006-2013)的Medicare 5%样本索赔数据选择样本。我们纳入了被诊断患有高血压和CKD的患者,并从2008年1月1日至2013年12月31日对其进行随访。然后,我们进行了时间依赖性生存分析,以评估遵守ACEI / ARB的长期利益。本研究中的药物依从性是通过覆盖天数(PDC)来衡量的。最后,我们使用地理加权回归模型(GWR)来研究药物依从性的危险因素。结果:大约50%的高血压CKD突发事件患者在首次确诊CKD后接受了指南推荐的ACEI / ARB。与没有这些药物的方案相比,包括ACEIs / ARBs和他汀类药物的抗高血压方案产生更好的CKD结果。此外,长期坚持使用ACEIs和ARBs可以显着降低终末期肾病(ESRD)的风险和长期死亡率。但是,只有61%的使用ACEI / ARB的高血压CKD的药物依从性良好(PDC≥80%)。居住在东北地区和中西部地区的患者表现出比居住在美国南部的患者更好的依从性。主要资源的可用性,邻里剥夺状态以及D部分低收入补贴(LIS)的覆盖范围是与药物依从性相关的因素。通过地图显示了背景特征和依从性之间的地理变化关联。结论:尽管美国老年高血压和CKD患者对CKD结局具有长期的显着益处,但指南推荐的ACEI / ARB的使用并不理想。在美国各地,对ACEI / ARB的遵守情况在地理位置上有所不同。从人群的角度来看,本研究中确定的情境和个人风险因素有助于设计局部区域的基于人群的策略以促进药物依从性。

著录项

  • 作者

    Han, Yun.;

  • 作者单位

    University of Michigan.;

  • 授予单位 University of Michigan.;
  • 学科 Social sciences education.
  • 学位 Ph.D.
  • 年度 2017
  • 页码 182 p.
  • 总页数 182
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:54:28

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号